Prof. Dr. Andreas Mackensen

Lehrstuhl für Innere Medizin V

Successful generation of fully human, second generation, anti-CD19 CAR T cells for clinical use in patients with diverse autoimmune disorders (2024) Mougiakakos D, Sengupta R, Gold R, Schroers R, Haghikia A, Lorente M, Pendleton M, et al. Journal article Blockade of the CD47/SIRPα checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab. (2024) Biedermann A, Patra-Kneuer M, Mougiakakos D, Büttner-Herold M, Mangelberger-Eberl D, Berges J, Kellner C, et al. Journal article CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series (2024) Auth J, Müller F, Völkl S, Bayerl N, Distler JH, Tur C, Raimondo MG, et al. Journal article Determinants Affecting the Clinical Implementation of a Molecularly Informed Molecular Tumor Board Recommendation: Experience from a Tertiary Cancer Center. (2023) Tögel L, Schubart C, Lettmaier S, Neufert C, Hoyer J, Wolff K, Moskalev E, et al. Journal article Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy (2023) Nunez D, Patel D, Volkov J, Wong S, Vorndran Z, Müller F, Aigner M, et al. Journal article Identification and characterization of T-cell receptors with therapeutic potential showing conserved specificity against all SARS-CoV 2 strains (2023) Reimann H, Moosmann C, Schober K, Lang V, Verhagen J, Zeun J, Mackensen A, et al. Journal article Inferior Outcomes of EU Versus US Patients Treated with CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use (2023) Bücklein V, Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, Penack O, et al. Journal article Targeted inhibition of protein synthesis renders cancer cells vulnerable to apoptosis by unfolded protein response (2023) Gsottberger F, Meier C, Ammon AM, Parker S, Wendland K, George R, Petkovic S, et al. Journal article Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19.CAR T-cell therapy (2023) Reimann H, Kremer A, Blumenberg V, Schmidt K, Aigner M, Jacobs B, Eisenhauer N, et al. Journal article, Letter Oxidative DNA damage in reconstituting T cells is associated with relapse and inferior survival after allo-SCT (2023) Karl F, Liang C, Böttcher-Loschinski R, Stoll A, Flamann C, Richter S, Lischer C, et al. Journal article